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The sympathetic nervous system of the heart is well known
as a key modulator of cardiac physiology and electrome-
chanical properties. Results of a wide spectrum of basic and
clinical studies, as well as the therapeutic success of anti-
adrenergic agents have provided proof that it plays an
important role in the development and progression of
cardiovascular disease. Yet, the quest for a better under-
standing of the clinical importance of the heart’s nervous
system continues, wherein novel approaches to guide and
improve therapy for heart failure and ischemic heart disease
are emerging.
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Targeted noninvasive imaging techniques have signiﬁ-
cantly contributed to progress in this regard. Nuclear
imaging approaches using radiolabeled catecholamines have
been successfully used to identify global and regional
impairments of sympathetic nerve terminals in the
myocardium and their contribution to disease development
and progression. Unique mechanistic insights have been
obtained using these techniques (1-3). Recently, a more
widespread clinical application has been supported by larger-
scale prospective clinical trials that conﬁrmed a prognostic
value of adrenergic imaging (4). Accordingly, the ﬁrst
radiolabeled catecholamine, iodine-123 meta-iodo-
benzylguanidine (MIBG) has been approved by the U.S.
Food and Drug Administration for clinical use in heart
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relevant to the contents of this paper to disclose.The setting, in which imaging of the cardiac sympathetic
nervous system is considered to be most valuable, is the
prediction of life-threatening arrhythmia and heart failure
progression. Reduced myocardial uptake of radiolabeled
catecholamines identiﬁes an impaired function of presyn-
aptic sympathetic nerve terminals (5). This is considered to
reﬂect impaired reuptake and thus impaired removal of the
neurotransmitter from the synaptic cleft, resulting in over-
exposure of the myocardium to catecholamines and in a pre-
synaptic/post-synaptic signaling imbalance (6). Such an
imbalance may lead to electrical vulnerability and progressive
loss of contractile function, which in turn contributes to
adverse outcomes. Consistent with this concept, the
prospective ADMIRE-HF (AdreView Myocardial Imaging
for Risk Evaluation in Heart Failure) trial showed that
reduced myocardial uptake of MIBG predicts adverse
outcomes in patients with heart failure (7). It is hoped that
this prognostic information, which was found to be incre-
mental over standard outcome markers, such as ejection
fraction, can be used to improve clinical decision making
with regard to the necessity of costly procedures such as
implantable devices. Direct proof from clinical studies that
combine innervation imaging with therapeutic decision
making in a prospective manner, however, is missing to date.
Another potential limitation of MIBG imaging is that
the main prognostic parameters, the heart-to-mediastinum
ratio and the cardiac washout rate, are derived from planar
scans of the chest. Tomographic images of the myocardium
are feasible using MIBG, and it has been suggested that
regional denervation of viable myocardium in the infarct
border zone may be an important contributor to arrhythmia.
But global downregulation of myocardial MIBG storage in
some individuals impairs image quality and complicates
defect size calculation, especially in the target group of heart
failure patients (8). Hence, positron emission tomography
(PET) may be a preferred technique for quantitative
assessment of the cardiac sympathetic nervous system. PET
provides superior sensitivity and resolution over conventional
nuclear imaging, and it holds the potential for absolute
quantiﬁcation of biological mechanisms. Various catechol-
amines have been labeled with positron emitting isotopes for
PET imaging (9), but to date, this high-end methodology
has been limited to small-scale mechanistic studies.
The PAREPET (Prediction of Arrhythmic Events with
Positron Emission Tomography) study (10), published in
this issue of the Journal, adds a new dimension to both
clinical myocardial innervation imaging and clinical PET
imaging. The authors set for themselves the ambitious scope
to perform complementary PET imaging of perfusion,
metabolism (i.e., viability), and sympathetic innervation in
a comparatively large group of subjects with ischemic
cardiomyopathy, and they performed long-term follow-up
to identify adverse events (11). In total, 204 patients
were recruited for 585 PET scans with [13N]-ammonia
(perfusion), [18F]-deoxyglucose (viability), and the cate-
cholamine analogue [11C]-hydroxyephedrine (HED). The
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151primary endpoint of sudden cardiac death or implantable
cardioverter-deﬁbrillator discharge occurred in 33 subjects
over a median follow-up of 4.1 years. Of note, the volume of
myocardium with reduced HED accumulation and the area
of ammonia/HED mismatch were independently predictive
of sudden cardiac death in this population, with highest
tertile exhibiting 3 times higher occurrence of the primary
endpoint compared with lower tertiles. The authors con-
structed a risk model encompassing 4 independent variables
in which the size of HED defect, left ventricle end-diastolic
volume index, creatinine levels, and absence of angiotensin
therapy demarcate cumulative risk for sudden cardiac death.
This study contributes to the growing evidence as to the
value of sympathetic neuronal imaging as predictive of lethal
arrhythmia. More importantly, it also shows that PET as
a high-end technology is ready for larger-scale clinical
imaging trials, in which its high accuracy for characterization
of biology on a regional myocardial level holds unique
potential.
Despite the major achievements of the PAREPET study
results, some limitations should be taken into account. First,
the authors do not make use of the full strength of PET
methodology because they do not provide a truly quantitative
analysis of HED uptake and retention in the myocardium.
HED analysis is limited to the calculation of a relative defect
on the basis of a (somewhat arbitrary) threshold of 75% of the
left ventricular maximum activity. Normalization to the
individual maximum may lead to inaccuracy of defect size
measurements in case of a global downregulation of myocar-
dial catecholamine storage. It is well known that heart failure
results in reduction of sympathetic innervation in the entire
myocardium (12,13). All patients in this study had cardio-
myopathy and thus may have global downregulation. If the
maximum region (used for normalization and set to 100%) is
reduced, then the overall defect size may be underestimated
after normalization. Calculation of a regional retention index
or, failing this, a standardized uptake value would provide
more concrete information on the severity and functional
consequence of the apparent HED reduction. According to
a limited analysis by the authors, the normalization factor
appears to be consistent, on the basis of the comparable
maximal retention indices provided. However, if the
normalization is completed to a retention index (%/min), then
presumably a regional analysis using this same retention index
calculation should be possible.
This observation is analogous to the experience with
myocardial perfusion PET imaging, wherein many larger-
scale clinical trials initially focused on relative regional
defects and refrained from absolute quantiﬁcation of
myocardial blood owing to the absence of well-established
clinical software for quantiﬁcation. This has changed only
recently, with larger studies emerging on the incremental
value of absolute ﬂow quantiﬁcation (14). A similar trend
may be encountered for cardiac neuronal PET imaging and
subsequent studies, even a re-analysis of the existing data
from the PAREPET study, which may lead to clinicalimplementation of absolute quantiﬁcation for catecholamine
retention. Clearly, it would be interesting to know how the
PAREPET study patients compare with a normal database,
and to determine the degree of reduction of HED accu-
mulation in the defect region and/or global myocardium.
Some other issues warrant discussion and/or speculation,
such as the impact of beta-blockers, angiotensin-converting-
enzyme inhibitors, or angiotensin receptor blockers, which
were all abundant in the PAREPET study population, or
the absolute value and relative effects of catecholamine levels
in the population (which were not reported). However, more
importantly, it should be noted that the wealth of PET-
derived information (perfusion, metabolism, innervation)
will allow for a series of subsequent analyses. The initial
inclusion of [18F]-deoxyglucose and ammonia to identify
hibernating myocardium is very useful. Interestingly, there
was a limited incidence of hibernating myocardium in this
patient population. The relationship between HED defects,
glucose metabolism, absolute ﬂow, and the presence of
stunned or hibernating myocardium would warrant some
further analysis. In pre-clinical work, the authors identiﬁed
sympathetic innervation defects by HED in association with
hibernating myocardium in a porcine model, with regional
abnormalities in the retention index identiﬁed in a 17-
segment model conﬁrming HED inhomogeneity (15).
Somewhat paradoxically, the HED defect persisted despite
improvement of left ventricular ejection fraction after
revascularization in the pigs with hibernating myocardium
(16). Along the same line, the PAREPET study results
demonstrate that the volume of HED defect is independent
of left ventricular ejection fraction. This raises some ques-
tions as to the therapeutic implications of the results. Would
PCI fail to improve sympathetic neuronal reuptake in the
long term in patients, similar to the porcine model? Also,
considering the relationship between innervation defect and
substrate for arrhythmia inducibility, would implantable
cardioverter-deﬁbrillator placement be the sole effective
option to counteract the arrhythmia risk?
The PAREPET study has been groundbreaking because
it shows that cardiac PET innervation imaging is feasible in
large clinical projects. It is another milestone for noninvasive
cardiac neuronal imaging, conﬁrming that losing its nerves is
not good for the heart and may get it out of rhythm.
Development of a Fluorine-18–labeled PET innervation
marker may be an important next step for more widespread
cardiac neuronal PET, but the PAREPET study also
suggests that development of robust absolute quantiﬁcation
algorithms, as well as design of prospective trials in which
imaging is combined with image test-driven therapy are
equally important next steps.
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